These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38365853)

  • 1. SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway.
    Zeng XC; Tian Y; Liang XM; Wu XB; Yao CM; Chen XM
    Diabetol Metab Syndr; 2024 Feb; 16(1):46. PubMed ID: 38365853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albuminuria and Serum Tumor Necrosis Factor Receptor Levels in Patients with Type 2 Diabetes on SGLT2 Inhibitors: A Prospective Study.
    Otoda T; Sekine A; Uemoto R; Tsuji S; Hara T; Tamaki M; Yuasa T; Tamaki T; Matsuhisa M; Aihara KI
    Diabetes Ther; 2024 Jan; 15(1):127-143. PubMed ID: 37883001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β
    Tian Y; Chen XM; Liang XM; Wu XB; Yao CM
    Sci Rep; 2022 Sep; 12(1):15695. PubMed ID: 36127497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
    Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
    Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels using mass spectrometer and urine albumin creatinine ratio as a predictor of development of diabetic nephropathy.
    Serdar M; Sertoglu E; Uyanik M; Tapan S; Akin K; Bilgi C; Kurt I
    Free Radic Res; 2012 Oct; 46(10):1291-5. PubMed ID: 22789030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
    Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
    Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes.
    Nunoi K; Sato Y; Kaku K; Yoshida A; Suganami H
    Endocrinol Diabetes Metab; 2018 Apr; 1(2):e00015. PubMed ID: 30815551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy.
    Dong Y; Shi S; Liu L; Zhou X; Lv J; Zhang H
    Front Med (Lausanne); 2023; 10():1242241. PubMed ID: 37736600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative stress markers in type 2 diabetes patients with diabetic nephropathy.
    Chou ST; Tseng ST
    Clin Exp Nephrol; 2017 Apr; 21(2):283-292. PubMed ID: 27233502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Baseline Clinical Variables on SGLT2i's Antiproteinuric Effect in Diabetic Kidney Disease.
    Capelli I; Ribichini D; Provenzano M; Vetrano D; Aiello V; Cianciolo G; Vicennati V; Tomassetti A; Moschione G; Berti S; Pagotto U; La Manna G
    Life (Basel); 2023 Apr; 13(4):. PubMed ID: 37109590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis.
    Ma C; Li X; Li W; Li Y; Shui F; Zhu P
    Int Urol Nephrol; 2023 Dec; 55(12):3167-3174. PubMed ID: 37046125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vivo study of the renoprotective effects of EGCG in diabetic db/db mice].
    Yang X; Li Y; Feng C; Guo L; Jin H
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(17):1330-5. PubMed ID: 27180749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes and various stages of proteinuria.
    Turk N; Mornar A; Mrzljak V; Turk Z
    Diabetes Metab; 2004 Apr; 30(2):187-92. PubMed ID: 15223992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation Between Serum 25-Hydroxyvitamin D Levels in Albuminuria Progression of Diabetic Kidney Disease and Underlying Mechanisms By Bioinformatics Analysis.
    Huang B; Wen W; Ye S
    Front Endocrinol (Lausanne); 2022; 13():880930. PubMed ID: 35634488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled.
    Ferreira JP; Zannad F; Butler J; Filippatos G; Pocock SJ; Brueckmann M; Steubl D; Schueler E; Anker SD; Packer M
    JAMA Cardiol; 2022 Nov; 7(11):1148-1159. PubMed ID: 36129693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study.
    Fu WJ; Xiong SL; Fang YG; Wen S; Chen ML; Deng RT; Zheng L; Wang SB; Pen LF; Wang Q
    Endocrine; 2012 Feb; 41(1):82-8. PubMed ID: 21779943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.
    Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Tanaka M; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    J Clin Med Res; 2018 Jun; 10(6):466-477. PubMed ID: 29707088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.